Retatrutide Peptide: FAQ Snippet

Ongoing clinical trials have shown promising safety profiles. However, full regulatory approvals are still in process, and current use is limited to research. 

ShiLai™ delivers pharmaceutical-grade peptides with full GMP compliance, strict in-house QC, and transparent documentation to support global research collaborations. 

Retatrutide activates three key metabolic receptors: GLP-1, GIP, and glucagon. This triple receptor agonism leads to improved glucose regulation, enhanced satiety, and accelerated fat loss, making it a promising candidate in obesity and type 2 diabetes management. 

ShiLai™ Retatrutide Peptide is produced at ≥ 99% purity level, validated through HPLC and MS analysis, ensuring consistency for clinical and pharmaceutical research applications.